Articles
& resources.

All
Articles
Events
Publications
Press

Press

September 1, 2026

+

FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities.

Articles

July 7, 2026

+

Unlocking the Potential of Antibody-Drug Conjugates in Cancer Therapy

Press

July 7, 2026

+

FluoSphera and Revvity Collaborate to Develop a Multiplexed Selectivity Assay for In Vitro Drug Discovery

Articles

July 7, 2026

+

FluoSphera secures $1 million pre-seed investment

Publications

July 7, 2026

+

FluoSphera S.A. is Grant Award Recipient of CHF 1.1 million from Innosuisse

Press

July 7, 2026

+

ENMEDIA Talks With FluoSphera

Press

July 7, 2026

+

LSCV Interview

Articles

July 7, 2026

+

Unlocking the Potential of Antibody-Drug Conjugates in Cancer Therapy

Articles

July 7, 2026

+

FluoSphera secures $1 million pre-seed investment

No items found.

Publications

July 7, 2026

+

FluoSphera S.A. is Grant Award Recipient of CHF 1.1 million from Innosuisse

Press

September 1, 2026

+

FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities.

Press

July 7, 2026

+

FluoSphera and Revvity Collaborate to Develop a Multiplexed Selectivity Assay for In Vitro Drug Discovery

Press

July 7, 2026

+

ENMEDIA Talks With FluoSphera

Press

July 7, 2026

+

LSCV Interview

partnership models

Predictive biology

From 3D tissues to integrated systems for better drug discovery decisions.

email
Name
company
message
Newsletter
Your submission has been received
Oops! Something went wrong while submitting the form.

starts today